A scientific publication in Cancers, a peer reviewed scientific journal, presents the capabilities of Acobiom’s GemciTest® to identify the pancreatic cancer patients who are most likely to benefit from gemcitabine-based treatment as the first approach.
In a recent study, ACOBIOM, in partnering with the Jerome Lejeune Institute, characterized molecular mechanisms that could help to better understand the decreased incidence of Breast Cancer in women with Down Syndrome (Trisomy 21).
AG2R LA MONDIALE supports the improvement of medical management of pancreatic cancer with GemciTest®
GemciTest®, an in-vitro diagnostic that predicts the patient’s response to one of the therapies used to treat pancreatic cancer, benefits now from CE marking, which means it complies with current European regulations in force. Acobiom develops innovative blood diagnostics in the field of precision medicine. These tests, based on liquid biopsies (blood), aim to give…
Read more
On next November 21, 2019, the World Pancreatic Cancer Day 2019 will be organized. Key information about pancreatic cancer Pancreatic cancer is one of the world’s deadliest cancers. This cancer develops when cells of the organs grow out of control, developing a tumor. The pancreas is a gland located deep in the abdomen, between the…
Read more
Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated with a clinical response to a specific therapy needs a tremendous combination of a scientific expertise, a biomolecular know-how, and a panel of bioinformatics and…
Read more
The Cancer Center (CGFL) of Dijon (France) launches a clinical study in 2018 to evaluate the prognostic value of on the overall survival and response to major treatments in patients diagnosed with pancreatic cancer. The CGFL is the sponsor of this study and the principal investigator is Professor François Ghiringhelli. In 2017, 14.000 new cases…
Read more
Acobiom became partner of the R-Link European program, which brings together 15 partners from 9 countries to develop a personalized approach to the medical care of patients suffering from bipolar disorders. This new approach is based on the discovery of biomarkers that predict lithium response. Acobiom, a company specializing in the discovery of biomarkers and…
Read more
Pancreatic cancer: the right treatment for the right patient Acobiom developed a diagnostic test to better target the treatment of pancreatic cancer patients. An innovation that should be on the market in 2019. 5%. The five-year survival rate of pancreatic cancer is extremely low. The Acobiom startup, located at the Euromedicine Biopole in Montpellier, wanted…
Read more
Metropolitain – 5/11/2017 START-UP: Biotech from Montpellier specialized in the discovery of new biological markers, Acobiom forecasts the launch of a test improving pancreatic cancer treatment Acobiom – 8 people including 6 researchers – works on the biomarker discovery and their association with drugs to improve the diagnostic and the efficiency of cancer treatment. Biotech…
Read more
